AVL-3288


Type I positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor

An isoxazole-acrylamide chemical entity originally developed at the University of California Irvine as compound CCMI and licensed through multiple owners to Anvylic Therapeutics, representing the most mechanistically distinct alpha-7 nicotinic candidate in clinical development through its Type I positive allosteric modulator mechanism that preserves the spatiotemporal specificity of endogenous cholinergic neurotransmission.

Abstract

AVL-3288 (also known as UCI-4083, CCMI, Anvylic-3288, and XY-4083) is a small-molecule, orally bioavailable Type I positive allosteric modulator (PAM) of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR). The compound is mechanistically distinct from the partial-agonist (tropisetron, encenicline, GTS-21) and full-agonist (bradanicline, PHA-543613) classes that have dominated alpha-7 nicotinic receptor drug development. Type I PAMs bind the alpha-7 receptor at an allosteric site distinct from the orthosteric (acetylcholine) binding site, do not directly activate the receptor in the absence of agonist, and enhance the potency and efficacy of endogenous acetylcholine signaling at the receptor. Critically, Type I PAMs preserve the rapid desensitization kinetics of the alpha-7 channel and therefore preserve the spatiotemporal specificity of cholinergic neurotransmission, in contrast to direct agonists which prolong receptor activation and may produce non-physiological signaling. This mechanistic profile is the principal scientific argument for the AVL-3288 approach as an alternative to direct agonist development in cognitive applications, particularly in light of the September 2015 FDA clinical hold and March 2016 Phase 3 termination of encenicline (a partial agonist) for severe gastrointestinal toxicity. The compound has not advanced to Phase 2 as of the most recent monograph revision; future development depends on commercial-funding decisions. AVL-3288 represents the most mechanistically novel of the alpha-7 nicotinic receptor candidates and is the principal contemporary alternative therapeutic concept for the alpha-7 nicotinic target. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph